|
ES8401486A1
(es)
|
1981-11-10 |
1983-12-01 |
Wellcome Found |
Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina.
|
|
US4847256A
(en)
|
1986-10-16 |
1989-07-11 |
American Cyanamid Company |
4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
|
|
AU650953B2
(en)
|
1991-03-21 |
1994-07-07 |
Novartis Ag |
Inhaler
|
|
US5728536A
(en)
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
|
US6136595A
(en)
|
1993-07-29 |
2000-10-24 |
St. Jude Children's Research Hospital |
Jak kinases and regulations of cytokine signal transduction
|
|
US5543523A
(en)
|
1994-11-15 |
1996-08-06 |
Regents Of The University Of Minnesota |
Method and intermediates for the synthesis of korupensamines
|
|
US5705625A
(en)
|
1994-12-15 |
1998-01-06 |
The Johns Hopkins University School Of Medicine |
Nucleic Acid Encoding novel protein tyrosine kinase
|
|
US7070972B1
(en)
|
1995-01-13 |
2006-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Janus family kinases and identification of immune modulators
|
|
JPH11508583A
(ja)
|
1995-07-06 |
1999-07-27 |
ゼネカ・リミテッド |
ペプチド系のフィブロネクチン阻害薬
|
|
US6248713B1
(en)
|
1995-07-11 |
2001-06-19 |
Biogen, Inc. |
Cell adhesion inhibitors
|
|
US7091020B1
(en)
|
1995-12-05 |
2006-08-15 |
Incyte Corporation |
Human Jak2 kinase
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
US6235741B1
(en)
|
1997-05-30 |
2001-05-22 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
|
FR2791562B1
(fr)
|
1999-03-29 |
2004-03-05 |
Oreal |
Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture
|
|
YU25500A
(sh)
|
1999-05-11 |
2003-08-29 |
Pfizer Products Inc. |
Postupak za sintezu analoga nukleozida
|
|
WO2001002400A1
(fr)
|
1999-07-02 |
2001-01-11 |
Eisai Co., Ltd. |
Composes imidazole fusionnes et medicaments contre le diabete sucre
|
|
OA12118A
(en)
|
1999-12-10 |
2006-05-04 |
Pfizer Prod Inc |
PyrroloÄ2,3-dÜpyrimidine compounds.
|
|
GB0028383D0
(en)
|
2000-11-21 |
2001-01-03 |
Novartis Ag |
Organic compounds
|
|
EP1241176A1
(fr)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Dérivés de purine pour le traitement de l'ischémie
|
|
AU2002361992A1
(en)
|
2001-12-20 |
2003-07-09 |
Bayer Aktiengesellschaft |
1,4-dihydro-1,4-diphenylpyridine derivatives
|
|
CA2483306A1
(fr)
|
2002-04-23 |
2003-11-06 |
Shionogi & Co., Ltd. |
Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive
|
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
|
US7161003B1
(en)
|
2002-09-04 |
2007-01-09 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
|
US7129239B2
(en)
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
|
EP1556053A4
(fr)
|
2002-10-31 |
2006-04-19 |
Amgen Inc |
Agents anti-inflammatoires
|
|
US7550470B2
(en)
|
2002-12-11 |
2009-06-23 |
Merck & Co. Inc. |
Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
|
|
EP1615697A2
(fr)
|
2003-04-11 |
2006-01-18 |
Novo Nordisk A/S |
Utilisation pharmaceutique de pyrazolo 1,5-a]pyrimidines substituees
|
|
WO2004089416A2
(fr)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Polytherapie utilisant un inhibiteur de type 1 de la 11beta-hydroxysteroide deshydrogenase et un agent hypotenseur dans le traitement du syndrome metabolique et des troubles et maladies associes
|
|
US20070270408A1
(en)
|
2003-04-11 |
2007-11-22 |
Novo Nordisk A/S |
Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
|
|
WO2004089415A2
(fr)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Therapie combinatoire utilisant un inhibiteur de 11$g(b)-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides pour minimiser les effets secondaires associes a la therapie a base d'agoniste du recepteur de glucocorticoides
|
|
WO2005004810A2
(fr)
|
2003-07-02 |
2005-01-20 |
Merck & Co., Inc. |
Derives arylsulfonamide
|
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
|
SE0302487D0
(sv)
|
2003-09-18 |
2003-09-18 |
Astrazeneca Ab |
Novel compounds
|
|
GB0329214D0
(en)
|
2003-12-17 |
2004-01-21 |
Glaxo Group Ltd |
Novel compounds
|
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
|
WO2005110477A2
(fr)
|
2004-04-09 |
2005-11-24 |
University Of South Florida |
Polytherapies pour le cancer et des angiopathies proliferantes
|
|
CA2565037A1
(fr)
|
2004-04-28 |
2005-11-10 |
Cv Therapeutics, Inc. |
Antagonistes du recepteur de l'adenosine a<sb>1</sb>
|
|
JP2008504294A
(ja)
|
2004-06-25 |
2008-02-14 |
アムジエン・インコーポレーテツド |
サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール
|
|
DE602005023763D1
(de)
|
2004-11-04 |
2010-11-04 |
Vertex Pharma |
Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
|
|
GB0502258D0
(en)
|
2005-02-03 |
2005-03-09 |
Argenta Discovery Ltd |
Compounds and their use
|
|
US20100216798A1
(en)
|
2005-07-29 |
2010-08-26 |
Astellas Pharma Inc |
Fused heterocycles as lck inhibitors
|
|
WO2007039797A1
(fr)
|
2005-10-03 |
2007-04-12 |
Pfizer Products Inc. |
Utilisation d'antagonistes du recepteur cannabinoide de type 1 pour traiter les inflammations et l'arthrite
|
|
PE20070543A1
(es)
*
|
2005-10-06 |
2007-06-14 |
Schering Corp |
Pirazolopirimidinas como inhibidores de protein quinasas
|
|
EP1931675B1
(fr)
|
2005-10-06 |
2015-01-14 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidines utilisees comme inhibiteurs de la proteine kinase
|
|
CA2626789A1
(fr)
|
2005-10-21 |
2007-04-26 |
Exelixis, Inc. |
Pyrimidinones en tant que modulateurs de caseine kinase ii (ck2)
|
|
US7795273B2
(en)
|
2005-12-08 |
2010-09-14 |
Novartis Ag |
Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
|
|
US8541406B2
(en)
|
2006-02-07 |
2013-09-24 |
Nv Remynd |
Thiadiazole derivatives for the treatment of neurodegenerative diseases
|
|
TW200800997A
(en)
|
2006-03-22 |
2008-01-01 |
Astrazeneca Ab |
Chemical compounds
|
|
AR061793A1
(es)
|
2006-07-05 |
2008-09-24 |
Mitsubishi Tanabe Pharma Corp |
Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
BRPI0718266A2
(pt)
|
2006-10-30 |
2014-01-07 |
Novartis Ag |
Compostos heterocíclicos como agentes anti-inflamatórios.
|
|
US20080176870A1
(en)
|
2006-11-20 |
2008-07-24 |
Bert Nolte |
Heterobicyclic metalloprotease inhibitors
|
|
WO2009017954A1
(fr)
|
2007-08-01 |
2009-02-05 |
Phenomix Corporation |
Inhibiteurs de kinase jak2
|
|
AU2008309517B2
(en)
|
2007-10-12 |
2013-03-14 |
Astrazeneca Ab |
Inhibitors of protein kinases
|
|
BRPI0819453A2
(pt)
|
2007-11-28 |
2014-10-07 |
Dana Farber Cancer Inst Inc |
Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit
|
|
AU2008345225A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
AU2009259853A1
(en)
|
2008-06-20 |
2009-12-23 |
Genentech, Inc. |
Triazolopyridine JAK inhibitor compounds and methods
|
|
WO2010019762A1
(fr)
|
2008-08-13 |
2010-02-18 |
Jenrin Discovery |
Composés de purine en tant que bloqueurs de récepteur aux cannabinoïdes
|
|
BRPI0914404A2
(pt)
|
2008-10-31 |
2019-03-06 |
Genentech Inc |
"compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente"
|
|
WO2010063487A1
(fr)
|
2008-12-05 |
2010-06-10 |
Merz Pharma Gmbh & Co. Kgaa |
Pyrazolopyrimidines, procédé pour leur préparation et leur utilisation comme médicament
|
|
CN102325765B
(zh)
|
2009-02-06 |
2014-12-24 |
杨森制药公司 |
作为γ-分泌酶调节剂的取代的双环杂环化合物
|
|
TWI461425B
(zh)
|
2009-02-19 |
2014-11-21 |
Janssen Pharmaceuticals Inc |
作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
|
|
UA110324C2
(en)
*
|
2009-07-02 |
2015-12-25 |
Genentech Inc |
Jak inhibitory compounds based on pyrazolo pyrimidine
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
EA022120B1
(ru)
|
2009-10-20 |
2015-11-30 |
Целльзом Лимитид |
Аналоги гетероциклил пиразолопиримидина в качестве ингибиторов jak
|
|
US20130096104A1
(en)
|
2010-03-17 |
2013-04-18 |
Genentech, Inc. |
Imidazopyridine compounds, compositions and methods of use
|
|
WO2011134831A1
(fr)
|
2010-04-30 |
2011-11-03 |
Cellzome Limited |
Composés de pyrazole comme inhibiteurs de jak
|
|
JP5985473B2
(ja)
|
2010-07-13 |
2016-09-06 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
|
|
WO2012075393A2
(fr)
|
2010-12-02 |
2012-06-07 |
President And Fellows Of Harvard College |
Activateurs de la dégradation protéasomique et leurs utilisations
|
|
EP2688872A4
(fr)
|
2011-03-22 |
2014-08-27 |
Merck Sharp & Dohme |
Inhibiteurs de kinases associées aux récepteurs d'interleukine à base d'amidopyrazole
|
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
|
EP2892899B1
(fr)
|
2012-09-06 |
2018-03-21 |
Bristol-Myers Squibb Company |
Inhibiteurs de jak3 de type imidazopyridazine et leur utilisation pour le traitement de maladies inflammatoires et auto-immunes
|
|
HUE047441T2
(hu)
|
2012-11-09 |
2020-04-28 |
Medicines For Malaria Venture Mmv |
Heteroaril-származékok és alkamazásaik
|
|
US20160166576A1
(en)
|
2013-07-11 |
2016-06-16 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
|
CA2929316C
(fr)
|
2013-11-08 |
2021-12-28 |
Takeda Pharmaceutical Company Limited |
Pyrazole pour le traitement de troubles auto-immuns
|
|
WO2015073267A1
(fr)
|
2013-11-15 |
2015-05-21 |
Calitor Sciences, Llc |
Composés hétéroaryle substitués et méthodes d'utilisation
|
|
HRP20210935T1
(hr)
|
2014-05-23 |
2021-08-06 |
F. Hoffmann - La Roche Ag |
Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
|
|
EP3145522B1
(fr)
|
2014-05-23 |
2020-12-23 |
Phibro Animal Health Corporation |
Combinaison, composition et méthode d'administration de la combinaison ou de la composition à des animaux
|
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
|
EP3215511B1
(fr)
|
2014-11-06 |
2024-04-17 |
Bial-R&D Investments, S.A. |
Pyrazolo(1,5-a)pyrimidines substituées et leur utilisation dans le traitement de troubles médicaux
|
|
US10040798B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of IRAK4 activity
|
|
US10329295B2
(en)
|
2015-03-12 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of IRAK4 activity
|
|
US10329294B2
(en)
|
2015-03-12 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of IRAK4 activity
|
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
|
TW201720828A
(zh)
|
2015-11-23 |
2017-06-16 |
赫孚孟拉羅股份公司 |
治療性化合物及組合物以及其使用方法
|
|
WO2017140825A1
(fr)
|
2016-02-18 |
2017-08-24 |
F. Hoffmann-La Roche Ag |
Composés thérapeutiques, leurs compositions et méthodes d'utilisation
|
|
MX2019007339A
(es)
|
2016-12-29 |
2019-09-06 |
Hoffmann La Roche |
Compuestos de pirazolopirimidina y metodos de uso de los mismos.
|
|
JP2020510061A
(ja)
|
2017-03-14 |
2020-04-02 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ピラゾロクロロフェニル化合物、組成物及びその使用方法
|
|
WO2018215390A1
(fr)
|
2017-05-22 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Composés thérapeutiques, compositions et procédés d'utilisation associés
|
|
JP7256757B2
(ja)
*
|
2017-05-22 |
2023-04-12 |
エフ． ホフマン－ラ ロシュ アーゲー |
処置用化合物及び組成物、並びにその使用方法
|